A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

NCT Number	NCT07667803
Lead Sponsor	AstraZeneca
Conditions	Weight Management
Enrollment	4,500 participants
Start Date	2026-07-06
Primary Completion	2028-07-31 (estimated)
Study Completion	2029-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-25